ViiV submits regulatory application to EMA for investigational HIV combo
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Read More
Tag: Edurant
Positive results for monthly HIV drug
Johnson & Johnson/ViiV’s once-monthly, injectable drug combination for HIV shows comparable efficacy to daily oral treatment in two trials.
Read More
ViiV’s long-acting two-drug HIV regimen hits targets
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
